KalVista Pharmaceuticals Stock Forecast, Price & News

KalVista Pharmaceuticals' stock was trading at $8.86 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, KALV stock has increased by 117.4% and is now trading at $19.26.
View which stocks have been most impacted by COVID-19.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for KalVista Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for KalVista Pharmaceuticals or view MarketBeat's top 5 stock picks.

Wall Street analysts have given KalVista Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but KalVista Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

KalVista Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, December 1st 2020.
View our earnings forecast for KalVista Pharmaceuticals.

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) issued its quarterly earnings results on Monday, September, 14th. The specialty pharmaceutical company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.60) by $0.01. KalVista Pharmaceuticals had a negative return on equity of 37.71% and a negative net margin of 229.45%.
View KalVista Pharmaceuticals' earnings history.

3 equities research analysts have issued 12 month target prices for KalVista Pharmaceuticals' stock. Their forecasts range from $25.00 to $39.00. On average, they expect KalVista Pharmaceuticals' stock price to reach $31.33 in the next twelve months. This suggests a possible upside of 62.7% from the stock's current price.
View analysts' price targets for KalVista Pharmaceuticals.

KalVista Pharmaceuticals saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 326,900 shares, an increase of 47.0% from the October 31st total of 222,400 shares. Based on an average trading volume of 85,400 shares, the short-interest ratio is presently 3.8 days. Approximately 2.8% of the company's stock are short sold.
View KalVista Pharmaceuticals' Short Interest.

Some companies that are related to KalVista Pharmaceuticals include Epizyme (EPZM), Ligand Pharmaceuticals (LGND), MacroGenics (MGNX), Phathom Pharmaceuticals (PHAT), Kiniksa Pharmaceuticals (KNSA), Ocular Therapeutix (OCUL), Karyopharm Therapeutics (KPTI), Cytokinetics (CYTK), Athenex (ATNX), Amneal Pharmaceuticals (AMRX), Zogenix (ZGNX), Travere Therapeutics (RTRX), Endo International (ENDP), Intercept Pharmaceuticals (ICPT) and Repare Therapeutics (RPTX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other KalVista Pharmaceuticals investors own include Heron Therapeutics (HRTX), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Catalyst Pharmaceuticals (CPRX), Corbus Pharmaceuticals (CRBP) and Pfizer (PFE).

KalVista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV."

KalVista Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.11%), Logos Global Management LP (1.68%), State Street Corp (1.46%), Boothbay Fund Management LLC (0.74%), Samsara BioCapital LLC (0.47%) and Wells Fargo & Company MN (0.28%). Company insiders that own KalVista Pharmaceuticals stock include Albert Cha, Andreas Maetzel, Benjamin L Palleiko, Christopher Yea, Daniel B Soland, Edward P Feener, Life Sciences Fund Iv (Gp) Sv, Svlsf Iv, Llc, Thomas Andrew Crockett and Venrock Healthcare Capital Par.
View institutional ownership trends for KalVista Pharmaceuticals.

KALV stock was sold by a variety of institutional investors in the last quarter, including Logos Global Management LP, Samsara BioCapital LLC, BlackRock Inc., JPMorgan Chase & Co., Alps Advisors Inc., Charles Schwab Investment Management Inc., and Morgan Stanley. Company insiders that have sold KalVista Pharmaceuticals company stock in the last year include Christopher Yea, and Thomas Andrew Crockett.
View insider buying and selling activity for KalVista Pharmaceuticals.

KALV stock was bought by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, State Street Corp, Boothbay Fund Management LLC, NEXT Financial Group Inc, California Public Employees Retirement System, BNP Paribas Arbitrage SA, Wells Fargo & Company MN, and California State Teachers Retirement System. Company insiders that have bought KalVista Pharmaceuticals stock in the last two years include Albert Cha, and Daniel B Soland.
View insider buying and selling activity for KalVista Pharmaceuticals.

Shares of KALV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of KALV stock can currently be purchased for approximately $19.26.

KalVista Pharmaceuticals has a market capitalization of $344.91 million and generates $12.69 million in revenue each year. The specialty pharmaceutical company earns $-29,120,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. KalVista Pharmaceuticals employs 56 workers across the globe.

The official website for KalVista Pharmaceuticals is www.kalvista.com.

KalVista Pharmaceuticals' mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The specialty pharmaceutical company can be reached via phone at 857-999-0075 or via email at [email protected]